Source: Medthority

AskBio: Phase II Gene Therapy Trial for CHF

First participant randomized in Europe for Phase II gene therapy trial of AB-1002 for congestive heart failure. AskBio & Bayer.

284

Est. Annual Revenue

$5.0-25M

Est. Employees

500-1.0K

CEO

Gustavo Pesquin

CEO Approval Rating

82/100

AskBio is a North Carolina-based biotechnology firm that researches and develops gene therapeutics for the treatment of genetic diseases.